Literature DB >> 26247447

Optimal design of perturbations for individual two-compartment pharmacokinetic analysis.

Matthew S Shotwell1, Minchun Zhou1, William H Fissell2.   

Abstract

We consider the optimal design of pharmacokinetic studies in patients that receive intermittent hemodialysis and intravenous antibiotic. Hemodialysis perturbs the pharmacokinetic system, providing additional opportunity for study. Designs that allocate measurements to occur exclusively during hemodialysis are shown to be viable alternatives to conventional designs, where all measurements occur outside of hemodialysis. Furthermore, hybrid designs with both conventional and intradialytic measurements have nearly double the efficiency of conventional designs. Convex optimal design and Monte Carlo techniques were used to simultaneously optimize hemodialysis event characteristics and sampling times, accounting for population pharmacokinetic heterogeneity. We also present several related methodological innovations.

Entities:  

Keywords:  Challenge response; hemodialysis; optimal design; pharmacokinetic; piperacillin; simulation; two-compartment model

Mesh:

Substances:

Year:  2015        PMID: 26247447      PMCID: PMC4744591          DOI: 10.1080/10543406.2015.1074918

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  15 in total

1.  Optimal sampling times in bioequivalence tests.

Authors:  F H Kong; R Gonin
Journal:  J Biopharm Stat       Date:  2000-02       Impact factor: 1.051

2.  Optimal design of mixed-effects PK/PD models based on differential equations.

Authors:  Yi Wang; Kent M Eskridge; Saralees Nadarajah
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

3.  First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.

Authors:  Jason A Roberts; Carl M J Kirkpatrick; Michael S Roberts; Andrew J Dalley; Jeffrey Lipman
Journal:  Int J Antimicrob Agents       Date:  2009-12-16       Impact factor: 5.283

Review 4.  Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy.

Authors:  Roger W Jelliffe
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

5.  Generalized solution to linear, to-compartment, open model for drug distribution.

Authors:  K B Bischoff; R L Dedrick
Journal:  J Theor Biol       Date:  1970-10       Impact factor: 2.691

6.  Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis.

Authors:  E L Francke; G B Appel; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

7.  Comparative pharmacokinetics of piperacillin in normals and in patients with renal failure.

Authors:  P J De Schepper; T B Tjandramaga; A Mullie; R Verbesselt; A van Hecken; R Verberckmoes; L Verbist
Journal:  J Antimicrob Chemother       Date:  1982-02       Impact factor: 5.790

8.  Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis.

Authors:  J A Giron; B R Meyers; S Z Hirschman; E Srulevitch
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

9.  Piperacillin pharmacokinetics in subjects with chronic renal failure.

Authors:  M I Thompson; M E Russo; J M Matsen; E Atkin-Thor
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

10.  Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.

Authors:  Fekade Bruck Sime; Michael S Roberts; Sandra L Peake; Jeffrey Lipman; Jason A Roberts
Journal:  Ann Intensive Care       Date:  2012-07-28       Impact factor: 6.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.